We are monitoring the impact of COVID-19 & Recession alarm on Ovarian Cancer Market Get in touch with us for detailed analysis Know More
Share on

Global Ovarian Cancer Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Stage of Cancer, Cancer Type, Diagnosis, Type of Treatment & Region – Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 1391
Pages: 181

Ovarian Cancer Market Size (2022 to 2027)

The size of the global ovarian cancer market is predicted to register a CAGR of 10.1% from 2022 to 2027.

The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spreads to the stomach and pelvis, a very advanced stage of ovarian cancer, which is fatal. A substantial percentage of women are dying due to ovarian cancer across the world. Ovarian cancer shows pious symptoms in the affected women, but they might experience pain in the abdomen, fatigue, indigestion, bloating, and nausea.


The rise in aged women's accounts and the increased prevalence of ovarian cancer worldwide are majorly accelerating the growth rate of the global ovarian cancer market.

The increasing economies of the countries in the developed and developing regions are leading to the expansion of healthcare. As a result, they are contributing to the growth of the global ovarian cancer market. The global ovarian cancer market is further predicted to develop in response to the growing geriatric population of women, the rise in ovarian cancer incidence, the ease of use of new treatments and therapies, and the increase in healthcare expenditure. In addition, increased government financing is also fuelling the market's expansion.

Ovarian cancer has become more common in recent years as the female population has aged. Some of the other important reasons driving the growth of the ovarian cancer market are rising ovarian cancer prevalence, the launch of new medications and therapies, increased healthcare expenditure, and increased government funding. Furthermore, growing healthcare awareness is propelling the ovarian cancer market forward. As a result, drugs like Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to enhance the market, now dominated by generics like paclitaxel and carboplatin. In addition, the market is expected to benefit significantly from the development of new medications to treat this form of cancer.

The global ovarian cancer treatment market is boosted by ongoing research and development to offer effective treatment interventions for various disorders. Several ovarian cancer treatments are now in clinical trials and are likely to hit the market in the near future. In addition, the patent expiration of certain top pharmaceuticals may also help propel the industry by encouraging new companies to enter the market. These altering dynamics are predicted to drive the ovarian cancer market during the forecast period.

Additionally, the increasing adoption rate of combination therapies for the treatment is another significant factor that catalyzes the growth of this market. Increased funding from governments and private organizations to research and develop effective treatment techniques and advanced therapeutics for treating ovarian cancer is boosting the worldwide ovarian cancer market.


Ovarian cancer symptoms are commonly ignored and readily confused with other illnesses, resulting in a lack of early identification and correct diagnosis. This is impeding the market for ovarian cancer diagnostics and treatments in Asia-Pacific. Ovarian cancer can spread to other organs such as the abdominal cavity, pelvis, and abdominal lymph nodes, bones, liver, brain, and the sac around the lymph nodes, among other things. Furthermore, the global market's expansion is being stifled by the expiration of significant medication patents. In the development of increasingly effective drugs, the market may confront a problem.

In addition, the unavailability of adequate technology for detecting ovarian cancer in the early stages is the major challenge limiting the growth of the global ovarian cancer market. Furthermore, the lack of skilled professionals is challenging the key players for the growth of the market. Also, the lack of funding for research and development activities is challenging the growth of the ovarian cancer market.

Impact of COVID-19 pandemic on the global ovarian cancer market:

The COVID-19 pandemic has negatively affected many countries across the globe. Several measures introduced to deal with the pandemic, such as lockdowns, reduction in trade activities, and shutdown of multiple factories and workplaces in several countries, could save lives; however, these measures have wide-ranging economic effects inducing economic contagion. Thus, along with the risk of a slowdown of global growth, the results of COVID-19 are adversely affecting various economic sectors in economies across the globe.

Key manufacturing segments have halted operations across the globe in response to the lockdown regulations issued by governments of various countries and discontinuing public transport services. In addition, amid the COVID-19 pandemic, the global ovarian cancer therapeutics market is witnessing significant operations changes.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Stage of Cancer, Diagnosis, Type of Treatment, Type of Cancer, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global ovarian cancer market has been segmented and sub-segmented based on the stage of cancer, diagnosis, type of treatment, type of cancer, and region.

 Ovarian Cancer Market - By Stage of Cancer:

  • Stage I
    • Stage IA
    • Stage IB
    • Stage IC
  • Stage II
    • Stage IIA
    • Stage IIB
    • Stage IIC
  • Stage III
    • Stage IIIA
    • Stage IIIB
    • Stage IIIC
  • Stage IV

Ovarian Cancer Market - By Cancer Type:

  • Primary Peritoneal Carcinoma
  • Ovarian Stromal Tumors
  • Ovarian Germ Cell Tumors
  • Epithelial Ovarian Tumors

The epithelial ovarian cancer segment is predicted to hold a leading share in the global market during the forecast period based on the cancer type. The rising population and growing awareness over the availability of treatment procedures bolstered the demand for this market. In addition, increasing incidences of ovarian cancer patients propel the growth rate of the ovarian low malignant potential tumor segment.

Ovarian Cancer Market - By Diagnosis:

  • Physical Examination
  • Blood Tests
  • Ultrasound
  • PET
  • CT Scan
  • MRI
  • Human Chorionic Gonadotropin Test
  • Biopsy

Ovarian Cancer Market - By Type of Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

Based on the type of treatment, Immunotherapy is dominating the market. It is presumed to grow at a high pace during the forecast period due to the continually increasing adoption rate of immunotherapy treatments and the expansion of healthcare, leading to the rise in the number of patients diagnosed with ovarian cancer undergoing immunotherapy.

The targeted therapy market is continuously increasing at a high rate of CAGR. It is likely to continue the trend during the forecast period due to the increasing popularity of targeted therapies and the rising prevalence of women affected by ovarian cancer.  

Ovarian Cancer Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America accounted for the leading share in the global ovarian cancer market in 2020. It is assumed to continue the trend during the outlook period due to the increasing pervasiveness of ovarian cancer and the geriatric population's growing account. The United States controls the highest share in the ovarian cancer diagnostics and therapeutics market and has added significantly. Ovarian cancer is the ninth most common cancer and the fifth leading cause of cancer death among women in the United States. Furthermore, most of the top global ovarian cancer diagnostics players are based in the United States. Therefore, it tends to be a significant advantage for the region, expected to drive the market.

Asia-Pacific demand is contributing a significant share of revenues to the market. It is likely to witness growth at high CAGR during the projection period due to the increasing prevalence of the aged population and the growing economies of countries like China and India. India and China are the fastest emerging countries in the Asia Pacific, owing to rising healthcare expenditures, increased government support, and an expanding target patient pool. Every year, more than 7 million new cancer cases are identified in Asia, according to the World Health Organization (WHO). China and India are regarded as two of the most promising countries globally, with substantial market prospects. Rising ovarian cancer incidence, favorable medical care reforms, increased health awareness, a low-cost base, and a lack of legal and cultural barriers contribute to the market's growth in India and China. As a result, the Asia-Pacific ovarian cancer diagnostics market is growing at a rapid pace.

Furthermore, the Asia-Pacific ovarian cancer diagnostics and therapeutics market is being fuelled by increased usage of combination treatments to treat ovarian cancer and rising healthcare spending in particular parts of the region. Ovarian cancer is becoming more common in China, which is leading the market. As a result, the projected incidence of ovarian cancer among Chinese women is rising.


Companies leading the global ovarian cancer market profiled in the report are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, and Genentech Inc.


  • GlaxoSmithKline plc has developed a novel drug for women diagnosed with advanced ovarian cancer. The company has approved a drug called zejula to the FDA in February 2020; the FDA aims for an efficient reviewing process to make it available for the patients.
  • In the recent studies, the researchers have identified a new drug fragment; as per the reports published by the research team, the pieces can help analyze the function of cancer protein leading to the development of drugs in the future.


                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods           

                1.4 General Study Assumptions

2. Research Methodology                           

                2.1 Introduction              

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

3. Overview                      

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 Epidemology             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                      

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market

5. Market Segmentation                              

                5.1 Stage Of Cancer        

                                5.1.1 Stage I




                                5.1.2 Stage II




                                5.1.3 Stage III




                                5.1.4 Stage IV

                                5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer

                                5.1.6 Market Attractiveness Analysis, By Stage Of Cancer

                                5.1.7 Market Share Analysis, By Stage Of Cancer

                5.2 Type              

                                5.2.1 Introduction

                                5.2.2 Primary Peritoneal Carcinoma

                                5.2.3 Ovarian Stromal Tumors

                                5.2.4 Ovarian Germ Cell Tumors

                                5.2.5 Epithelial Ovarian Tumors

                                5.2.6 Y-o-Y Growth Analysis, By Type

                                5.2.7 Market Attractiveness Analysis, By Type

                                5.2.8 Market Share Analysis, By Type

                5.3 Diagnosis     

                                5.3.1 Introduction

                                5.3.2 Physical Examination

                                5.3.3 Blood Tests

                                5.3.4 Ultrasound

                                5.3.5 PET

                                5.3.6 CT Scan

                                5.3.7 MRI

                                5.3.8 Human Chorionic Gonadotropin Test

                                5.3.9 Biopsy

                                5.3.10 Y-o-Y Growth Analysis, By Diagnosis

                                5.3.11 Market Attractiveness Analysis, By Diagnosis

                                5.3.12 Market Share Analysis, By Diagnosis

                5.4 Treatment  

                                5.4.1 Introduction

                                5.4.2 Chemotherapy

                                5.4.3 Radiation Therapy

                                5.4.4 Hormonal Therapy

                                5.4.5 Surgery

                                5.4.6 Immunotherapy

                                5.4.7 Targeted Therapy

                                5.4.8 Y-o-Y Growth Analysis, By Treatment

                                5.4.9 Market Attractiveness Analysis, By Treatment

                                5.4.10 Market Share Analysis, By Treatment

6. Geographical Analysis                              

                6.1 Introduction              

                                6.1.1 Regional Trends

                                6.1.2 Impact Analysis

                                6.1.3 Y-o-Y Growth Analysis






                                6.1.4 Market Attractiveness Analysis






                                6.1.5 Market Share Analysis






                6.2 North America          

                                6.1.1 Introduction

                                6.1.2 United States

                                6.1.3 Canada 

                6.3 Europe         

                                6.2.1 Introduction

                                6.2.2 U.K

                                6.2.3 Spain

                                6.2.4 Germany

                                6.2.5 Italy 

                                6.2.6 France

                6.4 Asia-Pacific 

                                6.3.1 Introduction

                                6.3.2 China 

                                6.3.3 India 

                                6.3.4 Japan 

                                6.3.5 Australia

                                6.3.6 South Korea

                6.5 Latin America            

                                6.4.1 Introduction

                                6.4.2 Brazil

                                6.4.3 Argentina

                                6.4.4 Mexico

                                6.4.5 Rest of Latin America

                6.6 Middle East & Africa

                                6.5.1 Introduction

                                6.5.2 Middle-East

                                6.5.3 Africa

7.Strategic Analysis                        

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

8.Market Leaders' Analysis                          

                8.1 Aetera Zenteris Inc.

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Financial analysis

                                8.1.4 Recent Developments

                                8.1.5 SWOT analysis

                                8.1.6 Analyst View

                8.2 Eli Lilly and Company             

                8.3 Roche           

                8.4 Amgen         

                8.5 Janssen Pharmaceuticals, Inc.             

                8.6 Bristol Myers Squibb Company          

                8.7 Novogen, Inc.            

                8.8 GlaxoSmithKline      

                8.9 Boehringer Ingelheim            

                8.10 AstraZeneca            

                8.11 Genentech Inc.       

9.Competitive Landscape                            

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis        

                9.3 Agreements, collaborations and Joint Ventures          

                9.4 New Product Launches          

10.Market Outlook and Investment Opportunities                           


                a) List of Tables

                b) List of Figures              

  1. Global Ovarian Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  2. Global Ovarian Cancer Market, By Stage Of Cancer, From 2022 - 2027 (USD Billion)
  3. Global Stage I Market, By Region, From 2022 - 2027 (USD Billion)
  4. Global Stage II Market, By Region, From 2022 - 2027 (USD Billion)
  5. Global Stage III Market, By Region, From 2022 - 2027 (USD Billion)
  6. Global Stage IV Market, By Region, From 2022 - 2027 (USD Billion)
  7. Global Ovarian Cancer Market, By Cancer Type, From 2022 - 2027 (USD Billion)
  8. Global Primary Peritoneal Carcinoma Market, By Region, From 2022 - 2027 (USD Billion)
  9. Global Ovarian Stromal Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  10. Global Ovarian Germ Cell Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  11. Global Epithelial Ovarian Tumors Market, By Region, From 2022 - 2027 (USD Billion)
  12. Global Ovarian Cancer Market, By Diagnosis, From 2022 - 2027 (USD Billion)
  13. Global Physical Examination Market, By Region, From 2022 - 2027 (USD Billion)
  14. Global Blood Tests Market, By Region, From 2022 - 2027 (USD Billion)
  15. Global Ultrasound Market, By Region, From 2022 - 2027 (USD Billion)
  16. Global PET Market, By Region, From 2022 - 2027 (USD Billion)
  17. Global CT Scan Market, By Region, From 2022 - 2027 (USD Billion)
  18. Global MRI Market, By Region, From 2022 - 2027 (USD Billion)
  19. Global Human Chorionic Gonadotropin Test Market, By Region, From 2022 - 2027 (USD Billion)
  20. Global Biopsy Market, By Region, From 2022 - 2027 (USD Billion)
  21. Global Ovarian Cancer Market, By Type Of Treatment, From 2022 - 2027 (USD Billion)
  22. Global Chemotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  23. Global Radiation Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  24. Global Hormonal Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  25. Global Surgery Market, By Region, From 2022 - 2027 (USD Billion)
  26. Global Immunotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  27. Global Targeted Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  28. Global Blood Glucose Monitoring Market, By Stage I, From 2022 - 2027 (USD Billion)
  29. Global Stage IA Market, By Region, From 2022 - 2027 (USD Billion)
  30. Global Stage IB Market, By Region, From 2022 - 2027 (USD Billion)
  31. Global Stage IC Market, By Region, From 2022 - 2027 (USD Billion)
  32. Global Blood Glucose Monitoring Market, By Stage II, From 2022 - 2027 (USD Billion)
  33. Global Stage IIA Market, By Region, From 2022 - 2027 (USD Billion)
  34. Global Stage IIB Market, By Region, From 2022 - 2027 (USD Billion)
  35. Global Stage IIC Market, By Region, From 2022 - 2027 (USD Billion)
  36. Global Blood Glucose Monitoring Market, By Stage III, From 2022 - 2027 (USD Billion)
  37. Global Stage IIIA Market, By Region, From 2022 - 2027 (USD Billion)
  38. Global Stage IIIB Market, By Region, From 2022 - 2027 (USD Billion)
  39. Global Stage IIIC Market, By Region, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports




pdf excel


pdf excel powerbi




What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.

Talk to our analyst and get customised report done according to your research needs


Check if you can avail any discount. Submit your details and our team will get back to you.


Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 4255

Didn’t find what you’re looking for?

Find it too expensive?

Click for Request Sample